Page 12«..11121314..2030..»

QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays

Posted: September 27, 2024 at 2:51 am

Product line earns CE-marking under new EU IVDR framework – including QIAstat-Dx Analyzer, QIAstat-Dx Rise and panels for detection of gastrointestinal and respiratory infections // Certification confirms that QIAGEN’s devices meet the stringent safety, quality and performance standards for in-vitro diagnostics in Europe // QIAGEN on track to transition over 180 products to new IVDR regulatory framework Product line earns CE-marking under new EU IVDR framework – including QIAstat-Dx Analyzer, QIAstat-Dx Rise and panels for detection of gastrointestinal and respiratory infections // Certification confirms that QIAGEN’s devices meet the stringent safety, quality and performance standards for in-vitro diagnostics in Europe // QIAGEN on track to transition over 180 products to new IVDR regulatory framework

Go here to see the original:
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays

Posted in Global News Feed | Comments Off on QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays

Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET

Posted: September 27, 2024 at 2:51 am

New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert

The rest is here:
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET

Posted in Global News Feed | Comments Off on Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Posted: September 27, 2024 at 2:51 am

SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist in development for the proposed treatment and long-term maintenance therapy of acromegaly.

Read more here:
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Posted in Global News Feed | Comments Off on Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

Posted: September 27, 2024 at 2:51 am

TARRYTOWN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2024 financial and operating results on Thursday, October 31, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Go here to read the rest:
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

Posted in Global News Feed | Comments Off on Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

Better Choice Company to Present at the 2024 ThinkEquity Conference and Provides Detail on Sales in China and the Acquisition of SRx Health

Posted: September 27, 2024 at 2:51 am

Sustained Sales Momentum in China in Q3 Following 37% Sequential Growth in Q2

See original here:
Better Choice Company to Present at the 2024 ThinkEquity Conference and Provides Detail on Sales in China and the Acquisition of SRx Health

Posted in Global News Feed | Comments Off on Better Choice Company to Present at the 2024 ThinkEquity Conference and Provides Detail on Sales in China and the Acquisition of SRx Health

Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update

Posted: September 27, 2024 at 2:51 am

-Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April and July-

Visit link:
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update

Posted in Global News Feed | Comments Off on Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update

Medicenna Announces Results of Annual Meeting of Shareholders

Posted: September 27, 2024 at 2:51 am

TORONTO and HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced the voting results from the Company’s annual meeting of shareholders held today, September 26, 2024 (the “Meeting”).

See original here:
Medicenna Announces Results of Annual Meeting of Shareholders

Posted in Global News Feed | Comments Off on Medicenna Announces Results of Annual Meeting of Shareholders

Qualigen Therapeutics, Inc. Announces management changes.

Posted: September 27, 2024 at 2:51 am

CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the Company regarding its future direction and strategic initiatives.

More:
Qualigen Therapeutics, Inc. Announces management changes.

Posted in Global News Feed | Comments Off on Qualigen Therapeutics, Inc. Announces management changes.

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on…

Posted: September 27, 2024 at 2:51 am

DURHAM, N.C., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced it will host a virtual KOL event on Monday, September 30, 2024 at 8:00 AM ET. To register, click here.

Excerpt from:
Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on...

Posted in Global News Feed | Comments Off on Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on…

Cassava Sciences Resolves SEC Investigation

Posted: September 27, 2024 at 2:51 am

AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission (“SEC”) of negligence-based disclosure charges that resolve a previously-disclosed SEC investigation into statements made by the Company pertaining to the results of its 2020 Phase 2b clinical trial of simufilam and related matters. Two former senior employees of the Company also settled negligence-based disclosure charges brought by the SEC.

Continue reading here:
Cassava Sciences Resolves SEC Investigation

Posted in Global News Feed | Comments Off on Cassava Sciences Resolves SEC Investigation

Page 12«..11121314..2030..»